Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors ar
4 of the Most Undervalued Stocks in the Market Right Now
08:47am, Monday, 11'th Aug 2025
In today's video, I will look at four stocks that have seen meaningful pullbacks and now appear undervalued. In a stock market that has largely been viewed as overvalued, not all stocks are participat
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class perio
NVO Investors are Reminded of Final Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
08:32am, Monday, 11'th Aug 2025
LOS ANGELES , Aug. 11, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the C
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or ac
As Novo Nordisk ramps up lawsuits over Wegovy copies, investors ask where is Hims?
06:09am, Monday, 11'th Aug 2025
In Novo Nordisk's legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers.
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Novo Nordis
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
09:20am, Sunday, 10'th Aug 2025
NEW YORK , Aug. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Novo Nordisk A/
Why I Tripled My Novo Nordisk Position
08:29am, Sunday, 10'th Aug 2025
Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below historical averages. Despite lowered 2025 guidance and slower growth, core products
2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold at Least a Decade
03:24am, Sunday, 10'th Aug 2025
Despite a recent dip in response to unfavorable economic data, the stock market's bull run seems unstoppable. From April 4 through Aug. 8, the S&P 500 index shot up a whopping 25.9%.
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such in
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
10:00am, Saturday, 09'th Aug 2025
This week, drugmakers had a scare when President Trump threatened to levy tariffs of up to 250% on imported pharmaceuticals. The news jolted the health care sector, which fell by 2.74% over the past f
Why Novo Nordisk Stock Flew Higher on Friday
07:00pm, Friday, 08'th Aug 2025
On Friday, the stock of Novo Nordisk (NVO 4.70%) continued to be affected by results from the lab the previous day. The interesting twist: It wasn't the company conducting the research.
Investors who lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO
04:27pm, Friday, 08'th Aug 2025
NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Novo Nordisk: This Won't Last
03:45pm, Friday, 08'th Aug 2025
Novo Nordisk is still the GLP-1 king, with over 65% market share and blockbuster drugs like Ozempic and Wegovy continuing to drive global growth. The recent stock correction presents a rare long-term
